Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telix Pharmaceuticals ( (AU:TLX) ) has issued an announcement.
Telix Pharmaceuticals has applied for quotation on the ASX of an additional 222,840 ordinary fully paid shares, issued following the exercise or conversion of existing options or other convertible securities. The new shares, dated 19 and 31 March 2026, modestly increase the company’s listed share capital and reflect ongoing utilisation of equity-based instruments by shareholders or holders of convertible securities.
The incremental listing strengthens Telix’s capital structure and marginally enhances its free float, providing additional tradable stock for investors. This routine corporate action signals continued engagement with the company’s equity programs and may marginally improve liquidity in Telix shares on the Australian market.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$31.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company listed on the ASX under the ticker TLX. The company operates in the pharmaceuticals sector, focusing on the development and commercialisation of medical products and technologies, with its ordinary fully paid shares traded on the Australian securities market.
Average Trading Volume: 3,164,933
Technical Sentiment Signal: Hold
Current Market Cap: A$4.6B
Learn more about TLX stock on TipRanks’ Stock Analysis page.